Antibodies targeting circulating protective molecules in lupus nephritis: Interest as serological biomarkers
- PMID: 30009962
- DOI: 10.1016/j.autrev.2018.03.013
Antibodies targeting circulating protective molecules in lupus nephritis: Interest as serological biomarkers
Abstract
Lupus nephritis (LN) is one of the most frequent and severe manifestations of systemic lupus erythematosus (SLE), considered as the major predictor of poor prognosis. An early diagnosis of LN is a real challenge in the management of SLE and has an important implication in guiding treatments. In clinical practice, conventional parameters still lack sensitivity and specificity for detecting ongoing disease activity in lupus kidneys and early relapse of nephritis. LN is characterized by glomerular kidney injury, essentially due to deposition of immune complexes involving autoantibodies against cellular components and circulating proteins. One of the possible mechanisms of induction of autoantibodies in SLE is a defect in apoptotic cells clearance and subsequent release of intracellular autoantigens. Autoantibodies against soluble protective molecules involved in the uptake of dying cells, including complement proteins and pentraxins, have been described. In this review, we present the main autoantibodies found in LN, with a focus on the antibodies against these protective molecules. We also discuss their pathogenic role and conclude with their potential interest as serological biomarkers in LN.
Keywords: Autoantibodies; Biomarkers; Circulating protective molecules; Lupus nephritis; Systemic lupus erythematosus.
Copyright © 2018. Published by Elsevier B.V.
Similar articles
-
Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis.Lupus. 2018 Sep;27(10):1582-1590. doi: 10.1177/0961203318773643. Epub 2018 May 3. Lupus. 2018. PMID: 29720035 Review.
-
[The roles of complement 1q and anti-C1q autoantibodies in pathogenesis of lupus nephritis].Zhonghua Yi Xue Za Zhi. 2005 Apr 13;85(14):955-9. Zhonghua Yi Xue Za Zhi. 2005. PMID: 16061001 Chinese.
-
Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis.Proteomics Clin Appl. 2015 Dec;9(11-12):1012-20. doi: 10.1002/prca.201400175. Epub 2015 Jun 12. Proteomics Clin Appl. 2015. PMID: 25824007 Free PMC article.
-
Effect of Autoantibodies to Erythropoietin Receptor in Systemic Lupus Erythematosus with Biopsy-proven Lupus Nephritis.J Rheumatol. 2016 Jul;43(7):1328-34. doi: 10.3899/jrheum.151430. Epub 2016 May 1. J Rheumatol. 2016. PMID: 27134248
-
Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review.J Autoimmun. 2016 May;69:1-11. doi: 10.1016/j.jaut.2016.02.003. Epub 2016 Feb 12. J Autoimmun. 2016. PMID: 26879422 Review.
Cited by
-
Pathogenic cellular and molecular mediators in lupus nephritis.Nat Rev Nephrol. 2023 Aug;19(8):491-508. doi: 10.1038/s41581-023-00722-z. Epub 2023 May 24. Nat Rev Nephrol. 2023. PMID: 37225921 Review.
-
Immune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis.Int J Mol Sci. 2021 Jul 1;22(13):7143. doi: 10.3390/ijms22137143. Int J Mol Sci. 2021. PMID: 34281193 Free PMC article. Review.
-
1,25-dihydroxyvitamin D3 ameliorates lupus nephritis through inhibiting the NF-κB and MAPK signalling pathways in MRL/lpr mice.BMC Nephrol. 2022 Jul 8;23(1):243. doi: 10.1186/s12882-022-02870-z. BMC Nephrol. 2022. PMID: 35804318 Free PMC article.
-
Microarray-based analysis of renal complement components reveals a therapeutic target for lupus nephritis.Arthritis Res Ther. 2021 Aug 25;23(1):223. doi: 10.1186/s13075-021-02605-9. Arthritis Res Ther. 2021. PMID: 34433493 Free PMC article.
-
IFN-γ Mediates the Development of Systemic Lupus Erythematosus.Biomed Res Int. 2020 Oct 17;2020:7176515. doi: 10.1155/2020/7176515. eCollection 2020. Biomed Res Int. 2020. PMID: 33123584 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical